Dupilumab improves sleep, function in people with chronic rhinosinusitis with nasal polyps: study Dr. Shravani Dali5 Jun 2022 8:00 PM ISTDupilumab improves sleep, and function in people with chronic rhinosinusitis with nasal polyps according to a recent study published in The Journal...
Sanofi Dupixent under USFDA priority review for adults with prurigo nodularis Ruchika Sharma31 May 2022 2:41 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Sanofi Dupixent gets USFDA nod for eosinophilic esophagitis Ruchika Sharma22 May 2022 10:00 AM ISTEoE is a chronic inflammatory disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly.
Dupilumab notably reduces hives and hitch in patients with chronic spontaneous urticaria: Study Medha Baranwal5 May 2022 10:15 AM ISTUSA: Results from a phase 3 trial revealed that dupilumab is well-tolerated and causes significant improvement in patients with H1...
Sanofi Dupixent under USFDA priority review for eosinophilic esophagitis patients Ruchika Sharma5 April 2022 11:30 AM ISTParis: Sanofi has recently announced that the U.S. Food and Drug Administration (USFDA) has accepted for Priority Review the supplemental Biologics...
Sanofi gets CDCSO panel okay to study Antiasthmatic drug Dupilumab Dr. Divya Colin9 March 2022 6:58 PM ISTNew Delhi: Pharmaceutical major, Sanofi has got the go-head from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization...
Setback: Sanofi to halt Dupixent Phase 3 trial MD Bureau21 Feb 2022 4:50 PM ISTParis: Sanofi has recently announced that the Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous...
Sanofi Dupixent under USFDA priority review for kids with atopic dermatitis Ruchika Sharma11 Feb 2022 12:23 PM ISTParis: Sanofi has recently announced that the U.S. Food and Drug Administration (USFDA) has accepted for Priority Review the supplemental Biologics...
Dupilumab effective in refractory bullous pemphigoid Dr Manoj Kumar Nayak5 Feb 2022 9:00 AM ISTDupilumab effective in refractory bullous pemphigoid1 Bullous pemphigoid (BP) is a subepidermal immunobullous disorder characterised by...
Sanofi, Regeneron get CHMP recommendation for Dupixent approval to treat severe asthma with type 2 inflammation in kids Ruchika Sharma1 Feb 2022 10:00 AM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Medicines Agency's Committee for Medicinal Products for Human...
Dupilumab helps treat moderate to severe asthma in kids Dr. Nandita Mohan18 Dec 2021 4:54 PM ISTA new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic...
Medical Bulletin 17/December/2021 Dr. Nandita Mohan17 Dec 2021 5:47 PM ISTHere are Top Medical stories of the day Dupilumab new treatment option for moderate-to-severe asthma in kids A new medication has been...
